{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Bauer A"],"funding":["Swiss National Science Foundation"],"pagination":["1841"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10385607"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15(7)"],"pubmed_abstract":["Activated leukocyte cell adhesion molecule (ALCAM) is a cell adhesion molecule that supports T cell activation, leukocyte migration, and (lymph)angiogenesis and has been shown to contribute to the pathology of various immune-mediated disorders, including asthma and corneal graft rejection. In contrast to monoclonal antibodies (mAbs) targeting ALCAM's T cell expressed binding partner CD6, no ALCAM-targeting mAbs have thus far entered clinical development. This is likely linked with the broad expression of ALCAM on many different cell types, which increases the risk of eliciting unwanted treatment-induced side effects upon systemic mAb application. Targeting ALCAM in surface-exposed tissues, such as the lungs or the cornea, by a topical application could circumvent this issue. Here, we repor"],"journal":["Pharmaceutics"],"pubmed_title":["Optimization and Characterization of Novel ALCAM-Targeting Antibody Fragments for Transepithelial Delivery."],"pmcid":["PMC10385607"],"funding_grant_id":["207060"],"pubmed_authors":["Halin C","Herbst A","Bauer A","Maccioni C","Kaluzhny Y","Abhamon W","Segueni N","Klassa S","Hunter MC"],"additional_accession":[]},"is_claimable":false,"name":"Optimization and Characterization of Novel ALCAM-Targeting Antibody Fragments for Transepithelial Delivery.","description":"Activated leukocyte cell adhesion molecule (ALCAM) is a cell adhesion molecule that supports T cell activation, leukocyte migration, and (lymph)angiogenesis and has been shown to contribute to the pathology of various immune-mediated disorders, including asthma and corneal graft rejection. In contrast to monoclonal antibodies (mAbs) targeting ALCAM's T cell expressed binding partner CD6, no ALCAM-targeting mAbs have thus far entered clinical development. This is likely linked with the broad expression of ALCAM on many different cell types, which increases the risk of eliciting unwanted treatment-induced side effects upon systemic mAb application. Targeting ALCAM in surface-exposed tissues, such as the lungs or the cornea, by a topical application could circumvent this issue. Here, we repor","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jun","modification":"2025-04-27T00:09:03.181Z","creation":"2025-04-06T17:44:48.956Z"},"accession":"S-EPMC10385607","cross_references":{"pubmed":["37514028"],"doi":["10.3390/pharmaceutics15071841"]}}